TY - JOUR
T1 - Advances in Urologic Imaging
T2 - Prostate-Specific Membrane Antigen Ligand PET Imaging
AU - Hofman, Michael S.
AU - Iravani, Amir
AU - Nzenza, Tatenda
AU - Murphy, Declan G.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/8
Y1 - 2018/8
N2 - Radiolabeled prostate-specific membrane antigen PET (PSMA PET) is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis and pave the way for personalized management of PCa.
AB - Radiolabeled prostate-specific membrane antigen PET (PSMA PET) is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis and pave the way for personalized management of PCa.
KW - PET
KW - PSMA PET
KW - PSMA PET/CT
KW - Prostate cancer
KW - Prostate-specific membrane antigen
UR - http://www.scopus.com/inward/record.url?scp=85048392273&partnerID=8YFLogxK
U2 - 10.1016/j.ucl.2018.03.016
DO - 10.1016/j.ucl.2018.03.016
M3 - Review article
C2 - 30031469
AN - SCOPUS:85048392273
VL - 45
SP - 503
EP - 524
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
SN - 0094-0143
IS - 3
ER -